The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan
Open accessAbstract
Background— The role of C-reactive protein (CRP) in heart failure is not well studied. We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan. Methods and Results— Characteristics of patients with baseline CRP levels above and below the median value were compared. Univariable and multivariable Cox proportional hazards regression models were used to examine the relationship of CRP to mortality and morbidity. Interactions were tested to determine whether differences in CRP changes from baseline to 4 and 12 months between groups randomly assigned to valsartan or placebo depended on baseline ACE inhibitor use. Median plasma CRP was 3.23 mg/L (interquartile range 1.42 to 7.56 mg/L), which is higher than in the general population. Patients with CRP above the median had features of more severe heart failure than those with CRP levels below the median. The cumulative likelihood of death and first morbid event increased with increasing quartile of CRP. Relative to the lowest CRP quartile, the risk of mortality (hazard ratio 1.51, 95% CI 1.2 to 1.9) and first morbid event (hazard ratio 1.53, 95% CI 1.28 to 1.84) was increased in the highest CRP quartile in multivariable models. CRP added incremental prognostic information to that provided by brain natriuretic peptide alone. CRP did not change significantly over time in the placebo group; however, after 12 months, valsartan was associated with a decrease in CRP in patients not receiving ACE inhibitors but not in those receiving ACE inhibitors at 12 months. Conclusions— CRP is increased in heart failure. Higher levels are associated with features of more severe heart failure and are independently associated with mortality and morbidity. The ability of treatments to reduce CRP levels and the prognostic importance of reducing CRP require further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationDanesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.102.18.2165 · Cited by 1,940
Verma, S., Wang, C.-H., Li, S.-H., Dumont, A. S., Fedak, P. W. M., Badiwala, M. V., Dhillon, B., Weisel, R. D., Li, R.-K., Mickle, D. A. G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000029802.88087.5e · Cited by 1,054
Ridker, P. M., Glynn, R. J., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.20.2007 · Cited by 1,013
Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study
Gottdiener, J. S., Arnold, A. M., Aurigemma, G. P., Polak, J. F., Tracy, R. P., Kitzman, D. W., Gardin, J. M., Rutledge, J. E., & Boineau, R. C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00582-9 · Cited by 907
Anand, I. S., Fisher, L. D., Chiang, Y.-T., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 864
Self-citationVasan, R. S., Sullivan, L. M., Roubenoff, R., Dinarello, C. A., Harris, T., Benjamin, E. J., Sawyer, D. B., Levy, D., Wilson, P. W. F., & D’Agostino, R. B. (2003) · Circulation · doi:10.1161/01.cir.0000057810.48709.f6 · Cited by 746
Verma, S., Li, S.-H., Badiwala, M. V., Weisel, R. D., Fedak, P. W. M., Li, R.-K., Dhillon, B., & Mickle, D. A. G. (2002) · Circulation · doi:10.1161/01.cir.0000015126.83143.b4 · Cited by 634
Inflammatory mediators in chronic heart failure: an overview
Anker, S. D., & von Haehling, S. (2004) · Heart · doi:10.1136/hrt.2002.007005 · Cited by 627
Biasucci, L. M., Liuzzo, G., Grillo, R. L., Caligiuri, G., Rebuzzi, A. G., Buffon, A., Summaria, F., Ginnetti, F., Fadda, G., & Maseri, A. (1999) · Circulation · doi:10.1161/01.cir.99.7.855 · Cited by 582
Basic mechanisms in heart failure: The cytokine hypothesis
Seta, Y., Shan, K., Bozkurt, B., Oral, H., & Mann, D. L. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80047-9 · Cited by 444
Baumann, H., & Gauldie, J. (1990) · PubMed · Cited by 326
Hypoxic Stress Induces Cardiac Myocyte–Derived Interleukin-6
Yamauchi-Takihara, K., Ihara, Y., Ogata, A., Yoshizaki, K., Azuma, J., & Kishimoto, T. (1995) · Circulation · doi:10.1161/01.cir.91.5.1520 · Cited by 304
Reduction in C-reactive protein through cardiac rehabilitation and exercise training
Milani, R. V., Lavie, C. J., & Mehra, M. R. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.041 · Cited by 302
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease.
Mendall, M. A., Patel, P., Asante, M., Ballam, L., Morris, J., Strachan, D. P., Camm, A. J., & Northfield, T. C. (1997) · Heart · doi:10.1136/hrt.78.3.273 · Cited by 282
Yin, W.-H., Chen, J.-W., Jen, H.-L., Chiang, M.-C., Huang, W.-P., Feng, A.-N., Young, M. S., & Lin, S.-J. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.11.021 · Cited by 192
DISEASE OF THE HEART IN THE WORKS OF HIPPOCRATES
Katz, A. M., & Katz, P. B. (1962) · Heart · doi:10.1136/hrt.24.3.257 · Cited by 169
Sato, Y., Takatsu, Y., Kataoka, K., Yamada, T., Taniguchi, R., Sasayama, S., & Matsumori, A. (1999) · Clinical Cardiology · doi:10.1002/clc.4960221211 · Cited by 163
Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction
Raymond, R. J., DEHMER, G. J., Theoharides, T. C., & Deliargyris, E. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113078 · Cited by 97
C-Reactive Protein in Dilated Cardiomyopathy
Kaneko, K., Kanda, T., Yamauchi, Y., Hasegawa, A., Iwasaki, T., Arai, M., Suzuki, T., Kobayashi, I., & Nagai, R. (1999) · Cardiology · doi:10.1159/000006913 · Cited by 96
Takeda, T., Hoshida, S., Nishino, M., Tanouchi, J., Otsu, K., & Hori, M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00158-8 · Cited by 89
Ajani, U. A., Ford, E. S., & Mokdad, A. H. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.036004 · Cited by 26
Cited by
Braunwald, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800239 · Cited by 1,257
Tsutsui, H., Isobe, M., Ito, H., Ito, H., Okumura, K., Ono, M., Kitakaze, M., Kinugawa, K., Kihara, Y., Goto, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0342 · Cited by 704
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Everett, B. M., Cornel, J. H., Lainscak, M., Anker, S. D., Abbate, A., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2019) · Circulation · doi:10.1161/circulationaha.118.038010 · Cited by 658
Myasoedova, E., Crowson, C. S., Kremers, H. M., Roger, V. L., Fitz-Gibbon, P. D., Therneau, T. M., & Gabriel, S. E. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135871 · Cited by 586
Pathophysiology of Heart Failure
Tanai, E., & Frantz, S. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140055 · Cited by 552
Metadata
- Authors
- Anand, I. S., Latini, R., Florea, V. G., Kuskowski, M. A., Rector, T., Masson, S., Signorini, S., Mocarelli, P., Hester, A., Glazer, R., & Cohn, J. N.
- Venue
- Circulation
- Published
- 2005-09-06
- Volume
- 112
- Issue
- 10
- Pages
- 1428-1434
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2167251312
- Cited by
- 456
- References
- 30
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.